MA63885B1 - Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer - Google Patents

Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer

Info

Publication number
MA63885B1
MA63885B1 MA63885A MA63885A MA63885B1 MA 63885 B1 MA63885 B1 MA 63885B1 MA 63885 A MA63885 A MA 63885A MA 63885 A MA63885 A MA 63885A MA 63885 B1 MA63885 B1 MA 63885B1
Authority
MA
Morocco
Prior art keywords
pi3k
methods
inhibit
compounds
treating cancer
Prior art date
Application number
MA63885A
Other languages
English (en)
Other versions
MA63885A1 (fr
Inventor
JR. David St. Jean
Original Assignee
Scorpion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics, Inc. filed Critical Scorpion Therapeutics, Inc.
Publication of MA63885A1 publication Critical patent/MA63885A1/fr
Publication of MA63885B1 publication Critical patent/MA63885B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent l'isoforme alpha de phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3Kα). Ces entités chimiques sont utiles, par exemple, pour traiter une affection, une maladie ou un trouble dans lesquels une activation accrue (par exemple, excessive) de PI3Kα contribue à la pathologie et/ou aux symptômes et/ou à la progression de l'affection, de la maladie ou du trouble (par exemple, un cancer) chez un sujet (par exemple, un être humain). Cette divulgation concerne également des compositions contenant lesdites entités, ainsi que des procédés d'utilisation et de fabrication de celles-ci.
MA63885A 2021-08-09 2022-08-08 Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer MA63885B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163231156P 2021-08-09 2021-08-09
PCT/US2022/039674 WO2023018636A1 (fr) 2021-08-09 2022-08-08 Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer

Publications (2)

Publication Number Publication Date
MA63885A1 MA63885A1 (fr) 2024-09-30
MA63885B1 true MA63885B1 (fr) 2025-01-31

Family

ID=83188497

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63885A MA63885B1 (fr) 2021-08-09 2022-08-08 Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer

Country Status (20)

Country Link
US (1) US20240343728A1 (fr)
EP (1) EP4363414A1 (fr)
JP (1) JP2024533975A (fr)
KR (1) KR20240051953A (fr)
CN (1) CN118159534A (fr)
AU (1) AU2022325819A1 (fr)
CA (1) CA3227902A1 (fr)
CL (1) CL2024000327A1 (fr)
CO (1) CO2024000448A2 (fr)
CR (1) CR20240045A (fr)
DO (1) DOP2024000019A (fr)
EC (1) ECSP24008488A (fr)
GE (1) GEAP202416449A (fr)
IL (1) IL310588A (fr)
JO (1) JOP20240020A1 (fr)
MA (1) MA63885B1 (fr)
MX (1) MX2024000708A (fr)
PE (1) PE20240652A1 (fr)
WO (1) WO2023018636A1 (fr)
ZA (1) ZA202401094B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097721A1 (fr) 2022-11-02 2024-05-10 Petra Pharma Corporation Ciblage de poches allostériques et orthostériques de phosphoinositide 3-kinase (pi3k) pour le traitement d'une maladie
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
WO2025036439A1 (fr) * 2023-08-16 2025-02-20 Laekna Pharmaceutical Ningbo Co., Ltd. Composés multicycliques et leur utilisation en tant qu'inhibiteurs de pi3k alpha
WO2025144931A1 (fr) * 2023-12-27 2025-07-03 Genesis Therapeutics, Inc. Méthodes de traitement du cancer
WO2025201503A1 (fr) * 2024-03-28 2025-10-02 InventisBio Co., Ltd. Composés, leurs procédés de préparation et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108074A2 (fr) * 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs de pi3 kinase
WO2011035855A1 (fr) * 2009-09-28 2011-03-31 Merck Patent Gmbh Dérivés de pyridinyl-imidazolone pour l'inhibition des kinases pi3
WO2017001645A1 (fr) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
WO2021001431A1 (fr) * 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
UA99469C2 (ru) * 2007-06-26 2012-08-27 Юсиби Фарма, С.А. Конденсированные производные тиазола как ингибиторы киназы
WO2011163195A1 (fr) * 2010-06-21 2011-12-29 Incyte Corporation Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k
SG11201610770PA (en) * 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
WO2017221272A1 (fr) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Procédé de préparation d'idélalisib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108074A2 (fr) * 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs de pi3 kinase
WO2011035855A1 (fr) * 2009-09-28 2011-03-31 Merck Patent Gmbh Dérivés de pyridinyl-imidazolone pour l'inhibition des kinases pi3
WO2017001645A1 (fr) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
WO2021001431A1 (fr) * 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas

Also Published As

Publication number Publication date
JOP20240020A1 (ar) 2024-02-01
CA3227902A1 (fr) 2023-02-16
JP2024533975A (ja) 2024-09-18
PE20240652A1 (es) 2024-04-04
DOP2024000019A (es) 2024-03-15
CR20240045A (es) 2024-02-20
CN118159534A (zh) 2024-06-07
ECSP24008488A (es) 2024-05-31
IL310588A (en) 2024-04-01
CO2024000448A2 (es) 2024-02-15
US20240343728A1 (en) 2024-10-17
AU2022325819A1 (en) 2024-02-29
ZA202401094B (en) 2025-05-28
EP4363414A1 (fr) 2024-05-08
MX2024000708A (es) 2024-02-08
GEAP202416449A (en) 2024-04-25
CL2024000327A1 (es) 2024-08-09
MA63885A1 (fr) 2024-09-30
KR20240051953A (ko) 2024-04-22
WO2023018636A1 (fr) 2023-02-16

Similar Documents

Publication Publication Date Title
ZA202311329B (en) Urea derivatives which can be used to treat cancer
JOP20240020A1 (ar) مركبات تثبط الصورة المتماثلة ألفا لـ pi3k وطرق لعلاج السرطان
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2023107723A3 (fr) Méthodes de traitement de troubles neurologiques
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
MA44948A1 (fr) Inhibiteurs de bace 1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
MX2025004073A (es) Métodos para tratar el cáncer
MX2024007062A (es) Compuestos heterociclicos como inhibidores de dyrk1a.
GEAP202416416A (en) Urea derivatives which can be used to treat cancer
EP2073635A4 (fr) Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer
UY39819A (es) Métodos para tratar el cáncer
PH12023551898A1 (en) Cyclic oxaphosphinane compounds and analogues thereof for treating fibrotic diseases
AR126147A1 (es) Derivados de urea para tratar el cáncer
MA34327B1 (fr) Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes
MX2025007377A (es) Inhibidores de jak2